Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

“…17 Previous studies have shown extensive myocardial involvement in adolescents with VAM in the absence of significant echocardiographic abnormalities. 4,8,9 However, marked variability in return to activity recommendations was noted in our study; almost one-half of the institutions indicated allowing these adolescents to return to full activity by 12 weeks. Only two-thirds of the institutions indicated considering a stress test prior to returning to full activity.…”

“…16 Thus, the findings of this multi-institutional study are consistent with recently published VAERS data and affirm the findings of prior smaller reports and case-series which suggest excellent short-term outcomes in these patients. [4][5][6][7][8][9][10]16 In addition, because the VAERS is critically dependent on reporting by practitioners and institutions, adverse events can be missed due to a lack of reporting. Our data, gathered from a large number of institutions across the US, provides an independent affirmation of the fact that serious life-threatening adverse events are extremely rare in adolescents with VAM.…”

“…1 The overall reported incidence of myopericarditis after administration of mRNA COVID-19 vaccine has been estimated to be 4.2 and 32.4 per million doses administered in females and males 12 through 17 years of age, respectively. 2,3 Case series 4 and several other reports suggest wide variability in clinical evaluation and treatment of adolescents 12-18 years of age with mRNA COVID-19 vaccine-associated myopericarditis (VAM) across institutions within the United States (US). [5][6][7][8][9][10] In order to better assess this variability, we conducted a cross-sectional survey of pediatric institutions across the US between July 9, 2021 and August 9, 2021.…”

Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis

“…Most (88%) cases occurred after the second dose of vaccine, and chest pain (100%) was the most common presenting symptom. Patients sought medical attention a median of 2 days after administration of the Pfizer mRNA COVID-19 vaccination [53]. Interestingly, most of these cases were mild and transient.…”

A case of myopericarditis with pleuritis following AstraZeneca Covid-19 vaccination

“…Myopericarditis occurred after vaccination has been reported following small pox, 3 DTaP, 4 and also post-Covid-19 vaccine injection. 5 Recent review shows Covid-19 vaccine-related myocardial injury usually presents in young Caucasian males with a median age of 36 years ago, at 3–10 days post-injection with. 6 Data suggest Covid-19 vaccine-related myocarditis or pericarditis are mostly associated with mRNA and rarely following the virus vector vaccine.…”